Currently, available predictive biomarkers for ICIs response, such as PD-L1 expression, tumor mutation burden, microsatellite instability and tumor infiltrating lymphocytes (TILs) are mainly confined to cancer itself or its associated TILs [6, 9]. This evidence concerns the gene CD274 and neoplasm.